AbbVie's Qulipta has become the first oral CGRP inhibitor to show efficacy in a phase 3 study involving women with menstrual ...

Jiangsu Hengrui Pharma's oral thrombopoietin (TPO) receptor agonist hetrombopag has been approved in China to treat low ...

The National Commission into the Regulation of AI in Healthcare has delivered its keenly anticipated report, which gives ...

Right after reporting encouraging data with its Dravet syndrome gene therapy, Encoded Therapeutics has raised an impressive ...

Gilead's twice-yearly injectable for pre-exposure prophylaxis (PrEP) of HIV, lenacapavir, will not be routinely funded by the ...

The pivotal QUINTESSENTIAL trial of the potentially first-in-class CAR-T showed a "statistically significant and clinically ...

Amgen's fast-growing cancer immunotherapy Imdelltra could move into the first-line setting in small cell lung cancer (SCLC), ...

Bayer has won FDA approval for oral HER2 inhibitor Hyrnuo as a first-line treatment for advanced HER2-mutant non-small cell ...

Europe is rapidly becoming a hub for next-generation CNS biomarker innovation, with advances in blood-based, digital and ...

The FDA has just started a priority review of Roche's anti-IL-6 inhibitor Enspryng (satralizumab) for MOGAD – myelin ...

Pharmaceutical firms are making an expensive mistake. They develop a drug, see it through clinical trials, and only then ...

Like LDL-cholesterol, elevated Lp (a) is recognised as an independent genetic risk factor for coronary artery disease, heart ...